Who: Boehringer Ingelheim and Circle Pharma
What: The German pharma has entered in a research and licensing collaboration with Circle Pharma to develop a first-in-class cyclin...
Boehringer Sees A Winner In Circle Pharma’s First-In-Class Cancer Approach
Deal Snapshot: Boehringer Ingelheim will work to develop a cyclin inhibitor that can stop cancer cell growth, using Circle’s macrocycle platform.
More from Deals
• By
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
• By
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
• By
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
• By
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
More from Business
• By
Multi-blockbuster falls short in a giant cell arteritis study.
• By
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
• By
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.